Veracyte (VCYT)
47.27
-1.46 (3.00%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13G/A VERACYTE, INC. Filed by: FMR LLC
June 5, 2026 10:13 AM - SEC Filing
Form 4 VERACYTE, INC. For: Jun 02 Filed by: McGuire Annie
June 4, 2026 9:39 PM - SEC Filing
Form 4 VERACYTE, INC. For: Jun 02 Filed by: Wygant Jonathan
June 4, 2026 9:39 PM - SEC Filing
Form 4 VERACYTE, INC. For: Jun 02 Filed by: Chambers Rebecca
June 4, 2026 9:39 PM - SEC Filing
Form 4 VERACYTE, INC. For: Jun 02 Filed by: Stapley Marc
June 4, 2026 9:39 PM - SEC Filing
Form 4 VERACYTE, INC. For: Jun 02 Filed by: Febbo Phillip G.
June 4, 2026 9:39 PM - SEC Filing
Form 4 VERACYTE, INC. For: Jun 02 Filed by: Leite John
June 4, 2026 9:39 PM - SEC Filing
Form 144 VERACYTE, INC. Filed by: McGuire Annie
June 4, 2026 4:33 PM - SEC Filing
Form 144 VERACYTE, INC. Filed by: Leite John
June 4, 2026 4:32 PM - SEC Filing
Form 144 VERACYTE, INC. Filed by: Stapley Marc
June 4, 2026 4:32 PM - SEC Filing
Form 144 VERACYTE, INC. Filed by: Chambers Rebecca
June 4, 2026 4:31 PM - SEC Filing
Canaccord Reiterates Hold Rating on Veracyte, Inc (VCYT)
June 2, 2026 6:53 AM - StreetInsider
Wolfe Research Assumes Veracyte, Inc (VCYT) at Outperform
June 1, 2026 4:23 PM - StreetInsider
Veracyte, Inc (VCYT) PT Raised to $57 at Needham
June 1, 2026 11:06 AM - StreetInsider
Veracyte launches Prosigna breast cancer test in US market
June 1, 2026 7:30 AM - StreetInsider
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
June 1, 2026 7:30 AM - BizWire
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
May 30, 2026 8:00 AM - BizWire
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
May 29, 2026 3:15 PM - BizWire
Form 4 VERACYTE, INC. For: May 22 Filed by: Wygant Jonathan
May 27, 2026 4:19 PM - SEC Filing
Form 4 VERACYTE, INC. For: May 20 Filed by: EPSTEIN ROBERT S
May 22, 2026 4:39 PM - SEC Filing
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
May 22, 2026 8:00 AM - BizWire
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
May 21, 2026 6:00 PM - BizWire
Form 144 VERACYTE, INC. Filed by: EPSTEIN ROBERT S
May 20, 2026 4:39 PM - SEC Filing
Veracyte to Participate in Upcoming Investor Conferences
May 19, 2026 4:05 PM - BizWire
Veracyte receives Medicare coverage for bladder cancer monitoring test
May 15, 2026 9:00 AM - StreetInsider
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
May 15, 2026 9:00 AM - BizWire
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
May 13, 2026 9:00 AM - Globe NewsWire
Form SCHEDULE 13G/A VERACYTE, INC. Filed by: Artisan Partners Limited Partnership
May 13, 2026 7:00 AM - SEC Filing
Form SCHEDULE 13G VERACYTE, INC. Filed by: STATE STREET CORP
May 12, 2026 12:19 PM - SEC Filing
Form 4 VERACYTE, INC. For: May 06 Filed by: McGuire Annie
May 8, 2026 4:25 PM - SEC Filing
Form 144 VERACYTE, INC. Filed by: McGuire Annie
May 6, 2026 4:26 PM - SEC Filing
Form SCHEDULE 13G/A VERACYTE, INC. Filed by: FMR LLC
May 6, 2026 11:41 AM - SEC Filing
Veracyte, Inc (VCYT) PT Raised to $52 at UBS
May 6, 2026 9:29 AM - StreetInsider
Form 10-Q VERACYTE, INC. For: Mar 31
May 6, 2026 8:08 AM - SEC Filing
Veracyte, Inc (VCYT) PT Raised to $42 at Canaccord
May 6, 2026 6:52 AM - StreetInsider
Veracyte (VCYT) Tops Q1 EPS by 19c, provides guidance
May 5, 2026 4:15 PM - StreetInsider
Form 8-K VERACYTE, INC. For: May 05
May 5, 2026 4:09 PM - SEC Filing
Veracyte Announces First Quarter 2026 Financial Results
May 5, 2026 4:05 PM - BizWire
Form SCHEDULE 13G VERACYTE, INC. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 2:35 PM - SEC Filing
Form SCHEDULE 13G VERACYTE, INC. Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
April 29, 2026 3:55 PM - SEC Filing
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
April 28, 2026 9:00 AM - BizWire
Form ARS VERACYTE, INC. For: Dec 31
April 22, 2026 4:12 PM - SEC Filing
Form DEF 14A VERACYTE, INC. For: Jun 10
April 22, 2026 4:10 PM - SEC Filing
Form DEFA14A VERACYTE, INC.
April 22, 2026 4:09 PM - SEC Filing
Veracyte, Inc (VCYT) PT Lowered to $40 at Canaccord
April 20, 2026 7:37 AM - StreetInsider
Form 4 VERACYTE, INC. For: Apr 10 Filed by: Haas Kevin Richard
April 14, 2026 5:03 PM - SEC Filing
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
April 14, 2026 4:05 PM - BizWire
Jefferies Starts Veracyte, Inc (VCYT) at Buy
April 13, 2026 3:24 AM - StreetInsider
Needham Reiterates Buy Rating on Veracyte, Inc (VCYT)
April 1, 2026 5:38 AM - StreetInsider
Veracyte, Inc (VCYT) PT Lowered to $45 at Guggenheim
March 30, 2026 7:10 AM - StreetInsider
Form SCHEDULE 13G/A VERACYTE, INC. Filed by: VANGUARD GROUP INC
March 27, 2026 1:53 PM - SEC Filing
Form 3 VERACYTE, INC. For: Mar 24 Filed by: Haas Kevin Richard
March 25, 2026 4:50 PM - SEC Filing
Form 8-K VERACYTE, INC. For: Mar 13
March 16, 2026 4:18 PM - SEC Filing
Veracyte appoints Kevin Haas as chief development and technology officer
March 16, 2026 4:15 PM - StreetInsider
Veracyte Names Kevin Haas as Chief Development and Technology Officer
March 16, 2026 4:15 PM - BizWire
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Wygant Jonathan
March 10, 2026 5:10 PM - SEC Filing
Form 4 VERACYTE, INC. For: Mar 06 Filed by: McGuire Annie
March 10, 2026 5:10 PM - SEC Filing
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Febbo Phillip G.
March 10, 2026 5:10 PM - SEC Filing
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Leite John
March 10, 2026 5:10 PM - SEC Filing
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Stapley Marc
March 10, 2026 5:10 PM - SEC Filing
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Chambers Rebecca
March 10, 2026 5:10 PM - SEC Filing
Full Article List
